Aclaris Therapeutics, Inc. (ACRS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Neal S. Walker D.O., M.D. | Co-Founder, President, Chairman & Interim CEO | 73.5k | -- | 1970 |
| Mr. Kevin Balthaser | Chief Financial Officer | 581.52k | -- | 1988 |
| Dr. Joseph Monahan Ph.D. | Chief Scientific Officer | 492.43k | -- | 1957 |
| Mr. James Loerop | Chief Business Officer | 570k | -- | 1965 |
| Mr. Matthew Rothman J.D. | General Counsel & Corporate Secretary | -- | -- | -- |
| Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry | -- | -- | -- |
| Mr. Steve Tucker | Senior Vice President of Project Leadership | -- | -- | -- |
| Mr. Ajay Aggarwal M.B.A., M.D. | Senior Vice President of Clinical Development | -- | -- | -- |
Aclaris Therapeutics, Inc.
- Sector:?
- Healthcare
- Industry:? Diagnostics & Research
- Full Time Employees:?
- 86
Description
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Corporate Governance
Upcoming Events
November 6, 2024 at 12:00 PM UTC
Aclaris Therapeutics, Inc. Earnings Date